English

• 4 Apr, 2023
  The nomination committee proposes changes to the board of Spago Nanomedical for increased commercial focus
• 29 Mar, 2023
  Spago Nanomedical publishes the annual report for 2022
• 2 Feb, 2023
  Spago Nanomedical year-end report January-December, 2022
• 10 Jan, 2023
  Spago Nanomedical publishes scientific paper on positive preclinical data with Tumorad® as treatment of solid tumors
• 23 Dec, 2022
  Spago Nanomedical terminates liquidity guarantee
• 8 Dec, 2022
  First patient dosed in Spago Nanomedical’s endometriosis Phase IIa clinical study
• 6 Dec, 2022
  Spago Nanomedical initiates clinical trial with SpagoPix in endometriosis and concludes SPAGOPIX-01
• 8 Nov, 2022
  Spago Nanomedical interim report January-September 2022
• 20 Oct, 2022
  Nomination committee appointed for the 2023 Annual General Meeting in Spago Nanomedical
• 19 Oct, 2022
  Meet Spago Nanomedical at Bio-Europe 2022